Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

abacavir, dolutegravir, lamivudine

ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE

abacavir, dolutegravir, lamivudine (ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 63
News articles 0
Drug details — abacavir, dolutegravir, lamivudine
US status
approved
Class
—
Route
—
Patents
20
Programs
63
Data quality
0.81
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

abacavir, dolutegravir, lamivudine (ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

Key facts

INN abacavir, dolutegravir, lamivudine
Brand ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE
Formulation TABLET

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline
  1. APHP200046 Phase 3 · PARItec · HPV vaccine
  2. APHP200068 Phase 3 · PARItec · Adult ICU patients with septic shock
  3. APHP230825 Phase 3 · PARItec · PEDIATRIC ACUTE MYOCARDITIS
  4. APHP240909 Phase 3 · PARItec · Patient with stabilized SSc-ILD (as defined by a decline of
  5. D9078C00001 Phase 3 · AstraZeneca · Patients With Locally Advanced (Stage III), Unresectable Non
  6. DR230333 Phase 3 · Tour Hekla · Intersitial lung disease related to systemic sclerosis
  7. FAT EMULSIONS , Triheptanoin Phase 3 · Anaxis Pharma · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
  8. IEDAT-04-2022 Phase 3 · Quince Therapeutics · Ataxia Telangiectasia

Related patents

Browse patents

  1. WO 2026114957

    DÉRIVÉS DE THIOPHÈNE 2-AMINO-3-CYANO SPIROCYCLIQUES ANNELÉS EN TANT QUE DÉGRADEURS DE KRAS POUR LE TRAITEMENT DU CANCER

    Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026114918

    DÉRIVÉS DE 2-AMINO-3-CYANO THIOPHÈNE ANNELÉS SPIROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KRAS POUR LE TRAITEMENT DU CANCER

    Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 20260146050

    KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES

    Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2026109631

    UTILISATION DE PROTÉINES ENGAGEANT LES LYMPHOCYTES T DANS LE TRAITEMENT DU CANCER

    Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2026099754

    MÉTHODE DE RÉDUCTION DE L'EXCRÉTION VIRALE, DE COLONISATION DE TISSU ET DE DÉPLÉTION LYMPHOÏDE PROVOQUÉES PAR OU ASSOCIÉES À UNE INFECTION PAR PCV2

    Expires Thu May 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2026093543

    TRAITEMENT COMBINÉ PAR AGONISTE DU GLP1R ET INHIBITEUR DE PCSK9

    Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2026094002

    COMBINAISONS DE MOLÉCULES D'ACTIVATION DE LYMPHOCYTES T BISPÉCIFIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DE TUMEURS SOLIDES EXPRIMANT CLAUDINE 18.2

    Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. WO 2026093542

    TRAITEMENT D'ASSOCIATION D'UN AGONISTE DU GLP1R ET D'UN INHIBITEUR DU SGLT-2

    Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2026093541

    SCHÉMAS POSOLOGIQUES POUR L'AZD5004

    Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2026093539

    MÉTHODES DE TRAITEMENT OU DE GESTION DE L'OBÉSITÉ

    Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2026093537

    MÉTHODES DE TRAITEMENT DU DIABÈTE

    Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 20260116870

    NOVEL NAV 1.1 POTENTIATORS

    Expires Wed Apr 25 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2026082715

    DÉPLÉTION DES MACROPHAGES ET VIRUS DE LA STOMATITE VÉSICULAIRE POUR LE TRAITEMENT DU CANCER

    Expires Wed Apr 18 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. WO 2026078163

    CONJUGUÉS COMPRENANT DES LIANTS

    Expires Wed Apr 11 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. WO 2026078165

    CONJUGUÉS COMPRENANT DES LIANTS CLIVABLES

    Expires Wed Apr 11 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 20260096994

    SOLID DISPERSIONS HAVING STABILIZED EMULSION PARTICLES

    Expires Wed Apr 04 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. WO 2026057740

    TRAITEMENT DU CANCER AVEC DES MOLÉCULES DE LIAISON THÉRAPEUTIQUES

    Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. WO 2026057582

    COMBINAISONS THÉRAPEUTIQUES D'UN INHIBITEUR D'AKT, D'UN INHIBITEUR DE BCL-2 ET D'UN GLUCOCORTICOÏDE

    Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. WO 2026046899

    PYRAZOLO[5,1-f][1,2,4]TRIAZIN-4-ONES EN TANT QU'INHIBITEURS DE NOX4

    Expires Wed Feb 28 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. WO 2026041123

    VACCINS À VECTEUR DEV CONTRE LA GRIPPE AVIAIRE

    Expires Wed Feb 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is abacavir, dolutegravir, lamivudine?

abacavir, dolutegravir, lamivudine (ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

What is the brand name for abacavir, dolutegravir, lamivudine?

ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE is a marketed brand name for abacavir, dolutegravir, lamivudine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of abacavir, dolutegravir, lamivudine?

abacavir, dolutegravir, lamivudine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.